ArticleStem cells international2012
Stem cells as in vitro model of Parkinson's disease.
Article in Stem cells international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Inhibition of PTPRS function does not affect the survival or regeneration of dopaminergic neurons but alters synaptic function in the nigrostriatal pathway.Neurobiology of disease · 2025Article
- New iPSC resource with long-read whole genome sequencing characterizations for enhanced in vitro modeling.bioRxiv : the preprint server for biology · 2025Article
- Unraveling the assembloid: Real-time monitoring of dopaminergic neurites in an inter-organoid pathway connecting midbrain and striatal regions.Materials today. Bio · 2024Article
- Blood-brain-barrier modeling with tissue chips for research applications in space and on Earth.Frontiers in space technologies · 2023Article
- Neurogenesis Is Increased in Human Neural Stem Cells by Aβ40 Peptide.International journal of molecular sciences · 2022Article
- Food Contamination: An Unexplored Possible Link between Dietary Habits and Parkinson's Disease.Nutrients · 2022Review
- A functional hiPSC-cortical neuron differentiation and maturation model and its application to neurological disorders.Stem cell reports · 2022Article
- Targeting the inflammasome in Parkinson's disease.Frontiers in aging neuroscience · 2022Article
- Therapeutic potential of pluripotent stem cell-derived dopaminergic progenitors in Parkinson's disease: a systematic review protocol.Systematic reviews · 2021Article
- Pluripotent Stem Cell Derived Neurons as In Vitro Models for Studying Autosomal Recessive Parkinson's Disease (ARPD): PLA2G6 and Other Gene Loci.Advances in experimental medicine and biology · 2021Article
- Impact of environmental neurotoxic: current methods and usefulness of human stem cells.Heliyon · 2020Review
- β-Carbolines in Experiments on Laboratory Animals.International journal of molecular sciences · 2020Article
- Physiological and pathological effects of amyloid-β species in neural stem cell biology.Neural regeneration research · 2019Review
- Aβ42 Peptide Promotes Proliferation and Gliogenesis in Human Neural Stem Cells.Molecular neurobiology · 2019Article
- Neuronal and Glial Differentiation of Human Neural Stem Cells Is Regulated by Amyloid Precursor Protein (APP) Levels.Molecular neurobiology · 2019Article
- 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling.Molecular neurodegeneration · 2018Review
- Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.Molecular neurobiology · 2015Review
- Different Tissue-Derived Stem Cells: A Comparison of Neural Differentiation Capability.PloS one · 2015Article
- Progress in stem cell therapy for major human neurological disorders.Stem cell reviews and reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progress in understanding neurodegenerative cell biology in Parkinson's disease (PD) has been hampered by a lack of predictive and relevant cellular models. In addition, the lack of an adequate in vitro human neuron cell-based model has been an obstacle for the uncover of new drugs for treating PD. The ability to generate induced pluripotent stem cells (iPSCs) from PD patients and a refined capacity to differentiate these iPSCs into DA neurons, the relevant disease cell type, promises a new paradigm in drug development that positions human disease pathophysiology at the core of preclinical drug discovery. Disease models derived from iPSC that manifest cellular disease phenotypes have been established for several monogenic diseases, but iPSC can likewise be used for phenotype-based drug screens in complex diseases for which the underlying genetic mechanism is unknown. Here, we highlight recent advances as well as limitations in the use of iPSC technology for modelling PD "in a dish" and for testing compounds against human disease phenotypes in vitro. We discuss how iPSCs are being exploited to illuminate disease pathophysiology, identify novel drug targets, and enhance the probability of clinical success of new drugs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.